Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection

Cheng, Chun-Yuan; Huang, Chien Chang; Leu, Ming-Sheng; Chiang, Chun Yi Fan; Wu, Mai Szu; Lai, Ping Chin

doi:10.1016/s0264-410x(97)00037-6

Cited by 19 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immune response to hepatitis B vaccine was also found to be lower in hemodialysis patients who were positive for anti-HCV [Navarro et al, 1996], probably because hemodialysis patients had low immune response to hepatitis vaccine [Stevens et al, 1984]. The controlled study of Cheng et al [1997] found the same immune response to hepatitis B vaccine in hemodialysis patients who were either anti-HCV positive or negative. Kamel et al [1994] also reported that HCV infection would not affect the immunogenicity of hepatitis B vaccine in healthy subjects.…”

Section: Discussionmentioning

confidence: 93%

Hepatitis B vaccination in patients with chronic hepatitis C

Lee

Chan

et al. 1999

J. Med. Virol.

View full text Add to dashboard Cite

The aim of the study was to evaluate the safety, immunogenicity, and possible therapeutic effect of hepatitis B vaccine in patients with chronic hepatitis C. The subjects studied included three groups: group I, 26 patients with chronic hepatitis C who were susceptible to hepatitis B virus infection; group II, 35 healthy subjects who were susceptible to both hepatitis B and hepatitis C virus infection; and group III, 30 patients with chronic hepatitis C receiving no hepatitis B vaccination as controls. Three 20 microg/dose of recombinant hepatitis B vaccines were given to subjects of groups I and II in months 0, 1, and 6. Blood samples from the subjects were collected before and 1 month after each dose of vaccination for serological testing. The subjects of groups I and II had similar antibody to hepatitis B surface antigen (anti-HBs) response rates after the first (30.8% vs. 17.1%), second (61.5% vs. 60.0%), and third (88.5% vs. 91.4%) doses of vaccination. Also, their geometric mean titers of anti-HBs did not differ much when vaccination completed in 7 months (360 vs. 581 mIU/ml). During vaccination period, patients with chronic hepatitis C demonstrated no significant change of serum cytokines and HCV RNA levels, but significantly lowered ALT levels after three doses of vaccination. Hepatitis B vaccination is safe and immunogenic in patients with chronic hepatitis C. It did not significantly affect their levels of HCV RNA, but tended to lower ALT levels.

show abstract

Section: Discussionmentioning

confidence: 93%

Hepatitis B vaccination in patients with chronic hepatitis C

Lee

Chan

et al. 1999

J. Med. Virol.

View full text Add to dashboard Cite

show abstract

“…[15][16][17][18][19][20] There are also some limitations that should be pointed out. First, the relatively short study period, although we evaluate the dialysis patients during 1 year follow up after vaccination, we expect that vaccinated patients will lose the protective anti-HBs titers (≥10 mIU/ml) during long term follow up, so we suggest that yearly reevaluate is necessary.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of hepatitis B vaccine responsiveness in hemodialysis and peritoneal dialysis patients

et al. 2015

View full text Add to dashboard Cite

“…The OR were not very different in the univariate and multivariate analysis, but the statistical significance was lost due to the small numbers. Several studies have demonstrated associations of gender, age, HD time, HCV infection, and number of vaccine doses with nonresponsiveness to HBV vaccine [17, 21, 22, 23]. Increased age has been shown to decrease vaccine response rate not only in healthy individuals but also in HD patients [23, 24, 25].…”

Section: Discussionmentioning

confidence: 99%

“…Of note, booster doses were given to these HD patients at intervals of at least 6 months. Vaccination schemes with shorter intervals (0, 1, 2, 6) seem to be more effective than the traditional three-dose scheme (0, 1, 6), since reasonable response is usually observed after the third dose [3, 21, 23, 29]. …”

Section: Discussionmentioning

confidence: 99%

Serological and Vaccination Profile of Hemodialysis Patients during an Outbreak of Hepatitis B Virus Infection

Lewis-Ximenez

Oliveira

Mercadante

et al. 2001

Nephron

View full text Add to dashboard Cite

During an outbreak of hepatitis B virus (HBV) infection in a hemodialysis unit, patients were assessed for serological viral markers and vaccination status. HBV infection was identified in 26 patients. Twenty of these were positive for hepatitis B surface antigen (HBsAg), and 6 were negative for HBsAg but positive for IgM antibody to hepatitis B core (anti-HBc) and HBV DNA. The primary source of infection was not clearly identified, although 2 patients were suspected to be the index cases. A multiple logistic regression analysis revealed low anti-HBs titers and vaccination status to be independently associated with the risk of acquiring HBV infection. Both the high prevalence of HBV infection (31%) detected in this unit and the low vaccine response (53%) observed reinforce the importance of universal and preventive measures in controlling HBV infection. The detection of HBV DNA in HBsAg-negative/IgM anti-HBc-positive patients emphasizes the value of anti-HBc testing in the routine screening of HBV in hemodialysis units.

show abstract

Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection

Cited by 19 publications

References 22 publications

Hepatitis B vaccination in patients with chronic hepatitis C

Hepatitis B vaccination in patients with chronic hepatitis C

Evaluation of hepatitis B vaccine responsiveness in hemodialysis and peritoneal dialysis patients

Serological and Vaccination Profile of Hemodialysis Patients during an Outbreak of Hepatitis B Virus Infection

Contact Info

Product

Resources

About